ALG.APV-527
Multispecific antibody
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05934539 NCT05934539 · Solid Tumors Registry: NCT05934539 | 1/2 | Number of participants with dose-limiting toxicities (DLTs) (28 days for Q2W); Overall Response Rate (Through completion of Expansion Phase. Approximately 24 months.) 2024-01-01 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Solid Tumors: Phase 1/2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| ALG.APV-527: this drug | Phase 1/2 | Multispecific antibody | 4-1BB (CD137) x 5T4 | not yet graded | No reviewed efficacy summary in this indication | |
| Larotrectinib | Approved | Small molecule | TRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions) | Weak signal | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Repotrectinib | Approved | Small molecule | ROS1/NTRK | not yet graded | No reviewed efficacy summary in this indication | |
| Selpercatinib (Retevmo) | Approved | Small molecule | RET | not yet graded | No reviewed efficacy summary in this indication | |
| CR-001 | Phase 1/2(overall) | Multispecific antibody | PD-1 + VEGF | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Dual-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Tumor antigen menu (TROP2, MSLN, B7-H3, HER2) | not yet graded | No reviewed efficacy summary in this indication | |
| EB-SELECT Single-Target CAR-NK Cells | Phase 1/2 | Cell therapy | Personalized, biomarker-guided allogeneic chimeric antigen receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Micvotabart Pelidotin | Phase 1/2 | Antibody–drug conjugate | ED-B domain of fibronectin | not yet graded | No reviewed efficacy summary in this indication | |
| Linebacker | —(overall) | Small molecule | PIM kinases (PIM1/2/3) | not yet graded | No reviewed efficacy summary in this indication | |
| RP3 | Discontinued | Oncolytic virus | Tumor cells (oncolytic replication) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.